Indian drugmakers on 3,000-job hiring push; Blood test IDs patients likely to respond to Tarceva;

 @FiercePharma: Celgene ushers Hugin into CEO suite. Article | Follow @FiercePharma

> Indian drugmakers are on hiring spree, with plans to recruit marketing and salespeople for some 3,000 new positions, according to the Economic Times. Report

> Testing for specific cancer protein markers in lung cancer patients' blood helps find those more likely to respond to Roche and OSI Pharmaceutials' Tarceva, new data show. Report

> MiddleBrook Pharmaceuticals, which develops and makes anti-infective products, said it filed for Chapter 11 bankruptcy protection. Report

> King Pharmaceuticals said it has completed its review of its Alpharma Animal Health business and has determined that it will not alter its current structure. Report

> The FDA has approved AstraZeneca and Pozen's pain drug Vimovo, an agency spokeswoman told Reuters. Report

> Endo Pharmaceuticals Holdings' first-quarter earnings climbed about 55 percent, largely on prior-year charges, while sales growth was solid. Report

> Leading Indian pharmaceutical firms such as Cipla, Ranbaxy, Pfizer, Dr Reddy's are among the firms pulled up by the Indian drug price regulator National Pharmaceuticals Pricing Authority for overcharging. Report

> The Office of the United States Trade Representative has expressed particular concern about the proliferation of counterfeit drugs in countries including Brazil, China, India, Indonesia and Russia. Report

Biotech News

 @FierceBiotech: Dendreon: Provenge to cost $93K for full course of treatment. Report | Follow @FierceBiotech 

 @JohnCFierce: The Provenge approval creates an illusion of fast progress with cancer vaccines; developers will soon be back to the same old snail's pace. | Follow @JohnCFierce

> Live from BIO: A human face for the drug industry. Story

> Valeant to buy orphan drug developer Aton for $318 million. Article

> Regulators delay a final decision on BMS' belatacept. Report

> Mass. biotech recruiters filling hundreds of positions. Item

> Promising liver data triggers spike in Raptor shares. Story

> Glenmark touts (much needed) $345M pain pact with Sanofi. Article

> Cancer vaccine developers bask in Provenge limelight. News

> Pozen poised for profits after Vimovo wins approval. Article

Biotech IT News

> My Job: Director for regulatory strategy at ISI. Story

> It's CROWNWeb vs. traditional data entry for renal studies. News

> Google spreadsheet aids multi-site data handling. Item

> As CDISC matures, service provider advocates data management. Article

> C-TASC's Thompson wins innovation award. Item

> Planning, stats modeling needed for adaptive trials. Report

And Finally... The hormone leptin, typically associated with body weight regulation, works within the central nervous system to aid the immune system's defense against sepsis, researchers found. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.